查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
无细胞 DNA 分离和萃取市场 - 全球及区域分析：按产品、平台、技术、应用、最终用户和区域 - 分析和预测（2025-2035 年）
市场调查报告书
商品编码
1703926

无细胞 DNA 分离和萃取市场 - 全球及区域分析：按产品、平台、技术、应用、最终用户和区域 - 分析和预测（2025-2035 年）

Cell-Free DNA Isolation and Extraction Market - A Global and Regional Analysis: Focus on Product, Platform, Techniques, Application, End User, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 130 Pages | 商品交期: 1-5个工作天内

价格
简介目录

由于癌症发病率不断上升、主要参与企业的倡议不断增多以及政府在无细胞 DNA 分离和提取市场中不断加大的倡议，无细胞 DNA 分离和提取试剂套件、试管和其他消耗品的使用量正在增加。

医疗保健公司持续大力投资以满足行业需求，以及主要终端用户越来越多地采用无细胞 DNA 分离和提取套件、试管和试剂是推动全球无细胞 DNA 分离和提取市场成长的主要因素。

全球无细胞 DNA 分离和萃取市场由老字型大小企业公司和新兴企业组成。一些公司正试图透过推出从不同样本类型中分离和提取无细胞 DNA 的新产品并为新产品开发筹集资金来保持其在市场上的地位。 2021 年 1 月至 2025 年 3 月期间，全球无细胞 DNA 分离和提取市场的主要市场参与企业已经看到了产品发布、产品核准、商业资金筹措和协同活动。该公司推出产品的倾向表明公司正在不断将新产品推向市场以分离无细胞 DNA，这主要是由于液态切片研究的增加和监管机构核准了几种液态切片检测。

本报告探讨的关键问题

  • 无细胞 DNA 分离和萃取如何彻底改变肿瘤学？
  • 全球无细胞 DNA 分离和提取市场的主要驱动因素、挑战和机会是什么？
  • 全球无细胞 DNA 分离和提取市场新兴趋势的底层结构是什么？
  • 为了在竞争激烈的市场中生存，主要企业正在实施哪些关键发展策略？
  • 已开发地区和发展中地区在使用无细胞 DNA 分离和提取进行标靶治疗的主要监管影响是什么？
  • 进入特定地区的公司预计会面临哪些潜在的进入障碍？
  • 预测期内（2025-2035 年），每个细分市场预计如何成长，预计每个细分市场将产生多少收益？以下是片段：
    • 产品（游离DNA萃取分离试剂套件、萃取分离管、其他耗材）
    • 平台（聚合酵素链锁反应（PCR）、次世代定序（NGS）、其他平台）
    • 技术（以微珠为基础、基于旋转管柱、其他技术）
    • 应用（非侵入性产前检测 (NIPT)、肿瘤学、移植排斥和其他应用）
    • 最终用户（製药和生物技术公司、学术和研究机构、CRO 和其他最终用户）
    • 地区（北美、欧洲、亚太地区、拉丁美洲、世界其他地区）
  • 企业发展地区的无细胞DNA分离和萃取公司有哪些成长机会？
  • 全球无细胞 DNA 分离和萃取市场中提供关键产品的主要企业有哪些？
  • 还有，这是为什么呢？

本报告概述了全球无细胞 DNA 分离和萃取市场，包括产品、平台、技术、应用、最终用户和地区的趋势，以及参与市场的公司概况。

目录

执行摘要

第一章 市场概述

  • 市场定义
  • cfDNA的早期检测与应用
  • cfDNA的特征
  • cfDNA的生物学作用
  • 循环cfDNA的提取
  • 循环cfDNA的应用
  • 市场足迹和成长潜力
  • 研究、临床开发和商业活动的中断

第二章全球无细胞 DNA 分离与萃取市场：产业分析

  • 概述
  • 美国法律要求与框架
    • FDA法规
  • 亚太地区的法律要求与框架
    • 中国
    • 日本

第三章 市场动态

  • 概述
  • 影响分析
  • 市场驱动因素
  • 市场限制
  • 市场机会

第四章 竞争格局

  • 概述
  • 产品发布和升级
  • 产品核可和商业融资
  • 协同效应活动
  • 合併与收购
  • 2023 年及 2024 年市场占有率分析（按公司）
  • 成长份额分析（按公司）

5. 全球无细胞DNA分离和提取市场（按产品）百万美元，2023-2035年

  • 概述
  • 无细胞DNA分离萃取试剂套件
  • 无细胞DNA分离萃取管
  • 其他耗材

6. 全球无细胞DNA分离与萃取市场（按平台划分），百万美元，2023-2035年

  • 概述
  • 次世代定序（NGS）
  • 聚合酵素链锁反应（PCR）
  • 即时聚合酵素链锁反应（RT-PCR）
  • 数位聚合酵素链锁反应（dPCR）
  • 其他的

7. 全球无细胞 DNA 分离与萃取市场（按技术划分），百万美元，2023-2035 年

  • 概述
  • 以微珠为基础
  • 基于旋转管柱
  • 其他的

8. 全球无细胞DNA分离与萃取市场（按应用），百万美元，2023-2035年

  • 概述
  • 非侵入性产前检测（NIPT）
  • 肿瘤学
    • 固态肿瘤
    • 造血系统恶性肿瘤
  • 移植排斥
  • 其他的

9. 全球无细胞DNA分离和提取市场（按最终用户划分），百万美元，2023-2035年

  • 概述
  • 製药和生物技术公司
  • 学术研究机构与研究中心
  • CRO
  • 临床诊断中心
  • 其他的

第 10 章。全球无细胞 DNA 分离和萃取市场（按地区划分，百万美元，2023 年至 2035 年）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 丹麦
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 新加坡
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 其他地区

第十一章 公司简介

  • Thermo Fisher Scientific Inc.
  • QIAGEN
  • Danaher Corporation
  • PerkinElmer, Inc.
  • Endress+Hauser AG
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • llumina, Inc.
  • Takara Bio Inc.
  • Aline Biosciences
  • EpiGentek Group, Inc.
  • Omega Bio-tek, Inc.
  • Promega Corporation
  • Streck, Inc.
  • AccuBioMed Co., Ltd.
  • AMSBIO
  • Covaris, Inc.
  • EntroGen, Inc.
  • NeoGeneStar LLC
  • Norgen Biotek Corporation
  • STRATEC SE
  • System Biosciences, LLC

第十二章调查方法

简介目录
Product Code: BHP0590SC

Introduction to Cell-free DNA Isolation and Extraction Market

The use of cell-free DNA isolation and extraction kits, tubes, and other consumables has increased due to the rising prevalence of cancer, the increasing key player initiatives, and the rising government initiatives in the cell-free DNA isolation and extraction market. The constant significant investments by healthcare companies to meet industry demand and the growing adoption of cell-free DNA isolation and extraction kits, tubes, and reagents among major end users are the major factors propelling the growth of the global cell-free DNA isolation and extraction market.

Competitive Landscape

The global cell-free DNA isolation and extraction market comprise well-established and newly emerging companies. Several companies are attempting to sustain their position in the market by launching new products and raising funds to develop new products for the isolation and extraction of cell-free DNA from different sample types. Key market players of the global cell-free DNA isolation and extraction market witnessed product launch, product approval and business funding, and synergistic activities majorly during the period January 2021-March 2025. The inclination of companies toward product launches suggests that the companies are involved in continuously bringing new products to the market to isolate cell-free DNA, which is primarily attributed to an increase in liquid biopsy studies and approval of several liquid biopsy assays by the regulatory agencies.

Market Segmentation:

Market Segmentation:

Segmentation 1: by Product

  • Cell-Free DNA Extraction and Isolation Kits
  • Extraction and Isolation Tubes
  • Other Consumables

Segmentation 2: by Platforms

  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Other

Segmentation 3: by Technique

  • Magnetic Beads-Based
  • Spin Column-Based
  • Other

Segmentation 4: by Application

  • Non-Invasive Prenatal Testing (NIPT)
  • Oncology
  • Transplant Rejection
  • Other Applications

Segmentation 5: by End User

  • Academic Research Institutes and Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Clinical Diagnostic Centers
  • Contract Research Organizations (CROs)
  • Others (Forensic, Biobanks)

Segmentation 6: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Rest-of-the-World

Key Questions Answered in the Report

  • How is cell-free DNA isolation and extraction revolutionizing oncology?
  • What are the major market drivers, challenges, and opportunities in the global cell-free DNA isolation and extraction market?
  • What are the underlying structures resulting in the emerging trends within the global cell-free DNA isolation and extraction market?
  • What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?
  • What are the key regulatory implications in developed and developing regions pertaining to the use of cell-free DNA isolation and extraction-targeted therapies?
  • What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
  • How is each market segment expected to grow during the forecast period 2025-2035, and what is the anticipated revenue to be generated by each segment? Following are the segments:
    • Product (Cell-Free DNA Extraction and Isolation Kits, Extraction and Isolation Tubes, Other Consumables)
    • Platform (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), and Other Platforms)
    • Technique (Magnetic Beads-Based, Spin Column-Based, and Other Techniques)
    • Application (Non-Invasive Prenatal Testing (NIPT), Oncology, Transplant Rejections, Other Applications)
    • End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Contract Research Organizations (CROs), and Other End Users)
    • Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
  • What are the growth opportunities for the cell-free DNA isolation and extraction companies in the region of their operation?
  • Who are the leading players with significant offerings in the global cell-free DNA isolation and extraction market?
  • Which companies are anticipated to be highly disruptive in the future, and why?

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Markets Overview

  • 1.1 Market Definition
  • 1.2 Early Discovery and Application of cfDNA
  • 1.3 Properties of cfDNA
  • 1.4 Biological Role of cfDNA
  • 1.5 Extraction of Circulating cfDNA
  • 1.6 Application of Circulating cfDNA
  • 1.7 Market Footprint and Growth Potential
  • 1.8 Interruption in Research and Clinical Development and Commercial Operation
    • 1.8.1 Research and Clinical Development
    • 1.8.2 Commercial Operation
    • 1.8.3 Navigating Crisis Recovery and Looking to the Future

2. Global Cell-Free DNA Isolation and Extraction Market: Industry Analysis

  • 2.1 Overview
  • 2.2 Legal Requirements and Framework in the U.S.
    • 2.2.1 FDA Regulation
  • 2.4 Legal Requirements and Framework in Asia-Pacific
    • 2.4.1 China
    • 2.4.2 Japan

3. Market Dynamics

  • 3.1 Overview
  • 3.2 Impact Analysis
  • 3.3 Market Drivers
  • 3.4 Market Restraints
  • 3.5 Market Opportunities

4. Competitive Landscape

  • 4.1 Overview
  • 4.2 Product Launch and Upgradations
  • 4.3 Product Approvals and Business Funding
  • 4.4 Synergistic Activities
  • 4.5 Mergers and Acquisitions
  • 4.6 Market Share Analysis (by Company), 2023 and 2024
  • 4.7 Growth Share Analysis (by Company)

5. Global Cell-Free DNA Isolation and Extraction Market (by Product) $Million, 2023-2035

  • 5.1 Overview
  • 5.2 Cell-Free DNA Isolation and Extraction Kits
  • 5.3 Cell-Free DNA Isolation and Extraction Tubes
  • 5.4 Other Consumables

6. Global Cell-Free DNA Isolation and Extraction Market (by Platform), $Million, 2023-2035

  • 6.1 Overview
  • 6.2 Next-Generation Sequencing (NGS)
  • 6.3 Polymerase Chain Reaction (PCR)
  • 6.4 Real-Time Polymerase Chain Reaction (RT-PCR)
  • 6.5 Digital Polymerase Chain Reaction (dPCR)
  • 6.6 Other Platforms

7. Global Cell-Free DNA Isolation and Extraction Market (by Techniques), $Million, 2023-2035

  • 7.1 Overview
  • 7.2 Magnetic Beads-Based
  • 7.3 Spin Column-Based
  • 7.4 Other Techniques

8. Global Cell-Free DNA Isolation and Extraction Market (by Application), $Million, 2023-2035

  • 8.1 Overview
  • 8.2 Non-Invasive Prenatal Testing (NIPT)
  • 8.3 Oncology
    • 8.3.1 Solid Tumor
    • 8.3.2 Hematological Malignancies
  • 8.4 Transplant Rejection
  • 8.5 Other Applications

9. Global Cell-Free DNA Isolation and Extraction Market (by End User), $ Million, 2023-2035

  • 9.1 Overview
  • 9.2 Pharmaceutical and Biotechnology Companies
  • 9.3 Academic Research Institutes and Laboratories
  • 9.4 Contract Research Organizations (CROs)
  • 9.5 Clinical Diagnostic Centers
  • 9.6 Other End Users

10. Global Cell-Free DNA Isolation and Extraction Market (by Region), $ Million, 2023-2035

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 France
    • 10.3.3 U.K.
    • 10.3.4 Italy
    • 10.3.5 Spain
    • 10.3.6 Denmark
    • 10.3.7 Rest-of-Europe
  • 10.4 Asia-Pacific
    • 10.4.1 China
    • 10.4.2 India
    • 10.4.3 Japan
    • 10.4.4 South Korea
    • 10.4.5 Australia
    • 10.4.6 Singapore
    • 10.4.7 Rest-of-Asia-Pacific (RoAPAC)
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest-of-Latin America (RoLA)
  • 10.6 Rest-of-the-World

11. Company Profiles

  • 11.1 Thermo Fisher Scientific Inc.
    • 11.1.1 Company Overview
    • 11.1.2 Product Portfolio
    • 11.1.3 Target Customers/End Users
    • 11.1.4 Analyst View
  • 11.2 QIAGEN
    • 11.2.1 Company Overview
    • 11.2.2 Product Portfolio
    • 11.2.3 Target Customers/End Users
    • 11.2.4 Analyst View
  • 11.3 Danaher Corporation
    • 11.3.1 Company Overview
    • 11.3.2 Product Portfolio
    • 11.3.3 Target Customers/End Users
    • 11.3.4 Analyst View
  • 11.4 PerkinElmer, Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Product Portfolio
    • 11.4.3 Target Customers/End Users
    • 11.4.4 Analyst View
  • 11.5 Endress+Hauser AG
    • 11.5.1 Company Overview
    • 11.5.2 Product Portfolio
    • 11.5.3 Target Customers/End Users
    • 11.5.4 Analyst View
  • 11.6 Agilent Technologies, Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Product Portfolio
    • 11.6.3 Target Customers/End Users
    • 11.6.4 Analyst View
  • 11.7 F. Hoffmann-La Roche Ltd.
    • 11.7.1 Company Overview
    • 11.7.2 Product Portfolio
    • 11.7.3 Target Customers/End Users
    • 11.7.4 Analyst View
  • 11.8 Merck KGaA
    • 11.8.1 Company Overview
    • 11.8.2 Product Portfolio
    • 11.8.3 Target Customers/End Users
    • 11.8.4 Analyst View
  • 11.9 llumina, Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Product Portfolio
    • 11.9.3 Target Customers/End Users
    • 11.9.4 Analyst View
  • 11.10 Takara Bio Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Product Portfolio
    • 11.10.3 Target Customers/End Users
    • 11.10.4 Analyst View
  • 11.11 Aline Biosciences
    • 11.11.1 Company Overview
    • 11.11.2 Product Portfolio
    • 11.11.3 Target Customers/End Users
    • 11.11.4 Analyst View
  • 11.12 EpiGentek Group, Inc.
    • 11.12.1 Company Overview
    • 11.12.2 Product Portfolio
    • 11.12.3 Target Customers/End Users
    • 11.12.4 Analyst View
  • 11.13 Omega Bio-tek, Inc.
    • 11.13.1 Company Overview
    • 11.13.2 Product Portfolio
    • 11.13.3 Target Customers/End Users
    • 11.13.4 Analyst View
  • 11.14 Promega Corporation
    • 11.14.1 Company Overview
    • 11.14.2 Product Portfolio
    • 11.14.3 Target Customers/End Users
    • 11.14.4 Analyst View
  • 11.15 Streck, Inc.
    • 11.15.1 Company Overview
    • 11.15.2 Product Portfolio
    • 11.15.3 Target Customers/End Users
    • 11.15.4 Analyst View
  • 11.16 AccuBioMed Co., Ltd.
    • 11.16.1 Company Overview
    • 11.16.2 Product Portfolio
    • 11.16.3 Target Customers/End Users
    • 11.16.4 Analyst View
  • 11.17 AMSBIO
    • 11.17.1 Company Overview
    • 11.17.2 Product Portfolio
    • 11.17.3 Target Customers/End Users
    • 11.17.4 Analyst View
  • 11.18 Covaris, Inc.
    • 11.18.1 Company Overview
    • 11.18.2 Product Portfolio
    • 11.18.3 Target Customers/End Users
    • 11.18.4 Analyst View
  • 11.19 EntroGen, Inc.
    • 11.19.1 Company Overview
    • 11.19.2 Product Portfolio
    • 11.19.3 Target Customers/End Users
    • 11.19.4 Analyst View
  • 11.20 NeoGeneStar LLC
    • 11.20.1 Company Overview
    • 11.20.2 Product Portfolio
    • 11.20.3 Target Customers/End Users
    • 11.20.4 Analyst View
  • 11.21 Norgen Biotek Corporation
    • 11.21.1 Company Overview
    • 11.21.2 Product Portfolio
    • 11.21.3 Target Customers/End Users
    • 11.21.4 Analyst View
  • 11.22 STRATEC SE
    • 11.22.1 Company Overview
    • 11.22.2 Product Portfolio
    • 11.22.3 Target Customers/End Users
    • 11.22.4 Analyst View
  • 11.23 System Biosciences, LLC
    • 11.23.1 Company Overview
    • 11.23.2 Product Portfolio
    • 11.23.3 Target Customers/End Users
    • 11.23.4 Analyst View

12. Research Methodology